Actively Recruiting
Evaluating Risankizumab for Treating Moderate to Severe Ulcerative Colitis in Children Aged 2 to Under 18 With Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension
Led by AbbVie · Updated on 2026-10-27
120
Participants Needed
73
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate how the drug Risankizumab works in children with moderate to severe ulcerative colitis UC, a disease causing inflammation and bleeding in the colon and rectum. The study focuses on pediatric participants aged 2 to under 18 years and assesses the drugs safety, how it moves through the body, and its impact on disease activity. The trial is sponsored by AbbVie and includes multiple groups based on age ranges. Participants will be divided into three cohorts by age 6 to under 18 years, 2 to under 6 years, and 2 to under 18 years. The study has three substudies an open-label induction phase lasting 12 weeks with intravenous Risankizumab a 52-week randomized, double-blind maintenance phase with subcutaneous Risankizumab at two different doses and a 208-week open-label extension where participants receive Risankizumab based on their response in the maintenance phase. During the trial, participants will attend regular hospital or clinic visits where medical assessments, blood tests, and questionnaires will monitor treatment effects and side effects. The study measures include drug concentration in the blood, clinical remission, symptom improvement, and adverse events. Follow-up continues for about 140 days after treatment to ensure safety and evaluate long-term outcomes.
CONDITIONS
Brief Title
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here